Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.11 +1.13%

+$0.05 today

Market cap
$630.03M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.90M

Average 1.76M

ABUS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Arbutus Biopharma CorporationNASDAQ: ABUS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 193.77M shares rose 1.6% year over year, in line with the +2.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.6% toward the trailing-twelve-month pace of +2.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
193.77M+1.1% QoQ
Last fiscal yearDec 2025
191.6M+3.2% YoY
LTMMar 2026
192.17M+2.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.6%——
1 year+3.2%——
3-year CAGR+8.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
191.6M USD
Year-over-year change
+3.2%
4-year CAGR
+15.9%

Weighted Avg Shares vs competitors

How ABUS compares with its peers on the latest reported figures

  • ABUS's LTM Mar 2026 weighted avg shares of 192.17M shares is the highest of the 9 companies compared; the peer median is 61.65M shares.
  • Its year-over-year change of +2.0% is the 6th highest of 8, against a peer median of +3.1%.
  • Over three fiscal years its annual growth of +8.3% compares with a peer median of +6.2%.
ABUS Competitors Peer median
Weighted Avg Shares for ABUS and competitors
Company Period LTM YoY 3-year CAGR
ABUSArbutus Biopharma CorporationLTM Mar 2026192.17M +2.0%+8.3%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026141.87M +6.5%+9.9%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026132.45M +2.6%+2.5%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
BNTCBenitec Biopharma Inc.LTM Mar 202643.27M +112.6%+166.1%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
Peer median (excluding ABUS) 61.65M+3.1%+6.2%

Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.99M39.02M18.14M6.17M14.08M
Cost of Revenue0000363K
Gross Profit10.99M39.02M18.14M6.17M13.72M
Gross Margin100.0%100.0%100.0%100.0%97.4%
Research & Development65.5M84.41M73.7M54.04M25.24M
Selling, General & Admin17.14M17.83M22.48M22.11M15.89M
Operating Expenses84.51M104.48M96.24M82.49M40.77M
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
EBITDA(71.64M)(61.86M)(70.99M)(68.4M)(33.04M)
EBITDA Margin-652.0%-158.5%-391.3%-1108.5%-234.6%
Operating Income(73.52M)(65.46M)(78.1M)(76.32M)(27.05M)
Operating Margin-669.1%-167.8%-430.5%-1236.7%-192.1%
Interest Income127K2.19M5.69M6.59M4.07M
Interest Expense2.86M1.73M459K137K97K
Other Income / Expenses(2.73M)444K5.25M6.4M(6.45M)
Income Before Tax(76.25M)(65.01M)(72.85M)(69.92M)(33.5M)
Pre-Tax Margin-693.9%-166.6%-401.6%-1133.0%-237.9%
Income Tax Expense04.44M000
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Net Margin-693.9%-178.0%-401.6%-1133.0%-237.9%
EPS (Basic)(0.73)(0.46)(0.44)(0.38)(0.17)
EPS (Diluted)(0.73)(0.46)(0.44)(0.38)(0.17)
Weighted Avg Shares106.24M150.94M165.96M185.61M191.6M
Weighted Avg Shares (Diluted)106.24M150.94M165.96M185.61M191.6M

Arbutus Biopharma Corporation

NASDAQ:ABUS

Intrinsic Alpha fair value

Locked

Current Price

$4.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.